Neurovision Correction (NVC)

IN THE NEWS

November 16, 2004 Wall Street Journal "Singapore Fashions Biotech Hub"

Patient Enrollment Form

Treat is available for patients from ! Just fill in the following form, and we will contact you.

Helpfull Links

Links to other web resources on Amblyopia and Lazy Eye

Patient Brochure

A brochure with information about the NVC treatment program. The information in this brochure is geared to patients and their relatives.

Testimonials!

Listen to actual patients and young adults' parents talk about the fundamental change NVC has brought to their lives.

Note
	Documents with this symbol require the free Adobe Acrobat reader available for free

NEURAL VISION CORRECTION (NVC^tm)

Patient Information

Clinician Information

Introduction

NeuroVision, Inc. - a medical technology company, has developed the NVC™ vision correction technology - a non-invasive, patient-specific treatment based on visual stimulation and facilitation of the neural connections responsible for vision. The NeuroVision AA1 System is a computerized system developed for the treatment of adult Amblyopia (Lazy Eye). The system has received FDA 510K marketing clearance indicating the treatment of Amblyopia for patients aged 9 years and above. Medical Service Options, Inc. (“MSO”) distribute NeuroVision’s AA1 Adult Amblyopia Treatment product in the US and Canada.

How it Works

The Amblyopia treatment is computer-based, composed of a series of about 30-40 sessions, usually 3 sessions per week. The computer-assisted part of the treatment is home-based or at a local eye-care professional.

Along the treatment course, the patient is monitored by a certified eye care provider who performs a comprehensive screening examination in order to assist in establishing patient’s eligibility to the treatment.

Treatment Results

The treatment results are individual, and the vision improvement level depends on patient's specific visual deficiencies

Among patients who participated in the clinical trials and had an initial visual acuity between 20/30 and 20/100, strabismic and / or anisometropic amblyopia, and less than 8 prism diopter strabismus, 80% achieved the following results:

Patients with initial visual acuity between 20/30 and 20/40 achieved a better than 20/25 visual acuity.
Patients with initial visual acuity between 20/40 and 20/50 achieved a better than 20/30 visual acuity.
Patients with initial visual acuity between 20/50 and 20/100 achieved a better than 20/40 visual acuity.

In addition to the improvement in the distance visual acuity, patients also achieved a remarkable improvement in binocular vision (the ability to use both eyes together) and in near vision.

Persistence tests, one year after the end of the treatment, demonstrate excellent stability in the achieved visual acuity.

MSO's role in NVC^TM Treatment

MSO retains marketing and distribution rights for the technology. Clinicians can prescribe treatment for their patients, or participate in MSO's franchise arrangement. For more information call MSO at (201) 670-9999.